21 March 2024

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Cambridge Cognition announces formation of new Scientific Advisory Board

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce the formation of a Scientific Advisory Board.

This expert board will provide scientific guidance and valuable market insights, primarily focusing on addressing emerging trends such as the integration of blood-based biomarkers, the collaborative possibilities for computerised cognitive assessments, and the benefits of diverse populations and patient meaningfulness for clinical trials. It will also review and advise on product strategies, scientific approaches, and evidence-generation for regulatory and data strategies.

The advisory board combines expertise covering CNS-related disorders, clinical development, and academia with a shared dedication to propelling brain health forward. With a wealth of experience in clinical development programmes, the board will support Cambridge Cognition in exploiting market trends effectively and ensuring its services and technologies continually adapt within the intricate and changing landscape for life science companies.  

The Scientific Advisory Board is chaired by Liam Kaufman, Vice President of Clinical Science and former CEO of Winterlight Labs, and is comprised of three founding members, highly qualified experts, namely:

·      Professor Judith Jaeger, PhD, who serves as owner and president of CognitionMetrics, LLC

·      Professor John Harrison, Chief Scientific Officer at Scottish Brain Sciences

·      Francesca Cormack, PhD, Chief Scientist at Cambridge Cognition

Professor Judith Jaeger is a neuropsychologist with over 35 years of experience in clinical and experimental neuropsychology and psychopathology. She is the owner and president of CognitionMetrics, LLC, a consultancy serving the pharmaceutical industry on early-phase and experimental medicine projects and pivotal and late-phase clinical programmes in CNS-affected diseases. She has represented pharmaceutical clients in regulatory meetings, including the FDA and Japan's PMDA. She is a Clinical Professor of Psychiatry and Behavioral Science at Albert Einstein College of Medicine, New York. She has authored over 90 peer-reviewed journal articles, several book chapters, co-edited books and hundreds of abstracts and presentations. Previously, she was Vice President for Clinical Trials at Cogstate, Inc. and Director of Clinical Development at AstraZeneca Pharmaceuticals, where she served as company-wide cognition and psychometrics expert. These industry positions followed a distinguished academic career as an NIH-funded research clinician and educator.

Professor John Harrison is an acknowledged cognition expert whose principal professional interest is in helping people understand, maintain, and enhance their cognitive skills. John is Chief Scientific Officer at Scottish Brain Sciences, a clinical trial and neuroscientific research company. In the past 25 years, John has assisted more than 80 CNS drug development organisations with selecting and successfully integrating cognitive testing into therapeutic development programmes. His work in Alzheimer's disease dates back to his participation in the studies of compound AN1792, for which he developed the Neuropsychological Test Battery (NTB). Variants of the NTB have since been a common feature of CNS-focused treatment development programmes. Work in psychiatric indications has included a key role in the development and registration of Brintellix. John is an associate professor at the AUmc Alzheimer Center and a visiting professor at King's College London. He holds Chartered Psychologist status and has authored/co-authored more than 100 books and scientific articles.

Matthew Stork, Chief Executive Officer of Cambridge Cognition, commented:

"With the emergence of disease-modifying therapies for Alzheimer's disease and progress in many other conditions, as well as the evolution of digital cognitive assessments, the landscape for CNS clinical research is rapidly evolving. Establishing the Scientific Advisory Board underscores our dedication to advancing the alignment of emerging trends in the sector. The board aims to deepen our understanding of customer requirements, assisting us to adapt rapidly to the evolving landscape while expanding the capabilities of our solutions."

Professor Judith Jaeger, PhD, commented:

"I'm delighted to have joined the Cambridge Cognition SAB and look forward to supporting the company's application of 30 years of cognitive science, plus the added value of Winterlight Labs' capabilities, to facilitate decision-making in developing new therapeutics affecting cognition. I am eager to contribute to Cambridge Cognition's continued growth in 2024 and beyond."

Professor John Harrison, commented:

 "I have more than 30 years' experience with the CANTAB system, first as a user, and between 1997 and 2000 as one of the team working on its development and validation. I have also had the good fortune to have worked with the Winterlight Labs team on their technology, which I regard as one of the most promising in the digital cognitive assessment space. It is, therefore, a huge pleasure to have the opportunity to shape the use and future development of these technologies as part of the Cambridge Cognition Scientific Advisory Board." 

Enquiries:

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit